IDO-expressing Fibroblasts Suppress the Development of Imiquimod-induced Psoriasis-like Dermatitis

Sanam Salimi Elizei1, Mohammadreza Pakyari1, Mehraneh Ghoreishi2,3, Ruhangiz Kilani1, Sanaz Mahmoudi1, and Aziz Ghahary1

Abstract
Psoriasis is a chronic skin condition whose pathogenesis is reported to be due to the activation of the interleukin-23/interleukin-17 (IL-23/IL-17) pathway. Here, we report that indoleamine 2,3-dioxygenase (IDO)-expressing fibroblasts reduce the activity of this pathway in activated immune cells. The findings showed that intralesional injection of IDO-expressing fibroblasts in imiquimod-induced psoriasis-like dermatitis on the back and ear (Pso. ear group) in mice significantly improves the clinical lesional appearance by reducing the number of skin-infiltrated IL-17+CD4+T cells (1.9% ± 0.3% vs. 6.9% ± 0.6%, n = 3, P value < 0.01), IL-17+γδ+T cells (2.8% ± 0.3% vs. 11.6% ± 1.2%, n = 3, P value < 0.01), IL-23+ activated dendritic cells (7.6% ± 0.9% vs. 14.0% ± 0.5%, n = 3, P < 0.01), macrophages (4.3% ± 0.1% vs. 11.3% ± 1.0%, n = 3, P value < 0.01), and granulocytes (2.5% ± 0.4% vs. 4.5% ± 0.3%, n = 3, P value < 0.01) as compared to untreated psoriatic mice. This finding suggests that IDO-expressing fibroblasts, and to a lesser extent, non-IDO primary fibroblasts suppress the psoriatic-like symptoms by inhibiting the infiltration of key immune cells involved in the development of psoriasis.

Keywords
IDO, psoriasis, IMQ, IL-17, IL-23, fibroblasts

Introduction
Psoriasis is one of the most common recurrent chronic inflammatory skin diseases, affecting 2% to 3% of the general population1. Recent studies demonstrated that interleukin-23 (IL-23) T helper 17 (Th17) pathway is linked to psoriasis2. It is reported that inflammatory myeloid dendritic cells expressing IL-23 initiate a set of signals that are crucial for the development and maintenance of Th173. The activated Th17 cells further secrete IL-17 and IL-22, which promote further recruitment of immune cells, keratinocyte proliferation, and sustained chronic inflammation3–5. There are several commercially available biological monoclonal antibodies (LY-2439821, AMG-827, and AZ17) at different phases of human clinical trials, which target the IL-23/IL-17 axis6,7. Although the use of these injectable biologics is far more effective than other treatments, the cost and high risk of side effects make them still less desirable. This is because patients treated with anti-IL-12 and/or IL-23 cytokine showed potential opportunistic infections such as salmonellosis and mycobacterial. These reports showed that immunity against these microorganisms depends on the expression of IL-12 and/or IL-238,9. As such, there is still a need to find a new strategy through which psoriasis can be treated without compromising the functionality of the immune system and any potential side effects.

Indoleamine 2,3-dioxygenase (IDO), which is a cytosolic rate-limiting enzyme and is mainly expressed by macrophages, dendritic cells, and trophoblasts, breaks down

1 Division of Plastic Surgery, Department of Surgery, BC Professional Firefighters’ Burn and Wound Healing Research Laboratory, University of British Columbia, Vancouver, British Columbia, Canada
2 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada
3 Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada

Submitted: June 05, 2017. Revised: September 13, 2017. Accepted: September 18, 2017.

Corresponding Author:
Aziz Ghahary, Division of Plastic Surgery, Department of Surgery, BC Professional Firefighters’ Burn and Wound Healing Research Laboratory, University of British Columbia, 4550 ICORD, 818 10th Avenue West, Vancouver, British Columbia, Canada VSZ 1M9. Email: aghahary@mail.ubc.ca

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
tryptophan (Trp)\textsuperscript{10}. The expression of IDO by antigen-presenting cells (APCs) in vivo allows them to suppress unwanted T cell responses\textsuperscript{11}. Our studies found that IDO-expressing primary dermal fibroblasts suppress inflammatory cell proliferation and induce apoptotic death in some subsets of T lymphocytes, but not skin cells\textsuperscript{12}. These findings let us ask the question of whether intraleisional injection of IDO-expressing fibroblasts in a previously used imiquimod (IMQ; Aldara cream) psoriatic mouse model\textsuperscript{13} improves the psoriatic clinical appearance by modulating the IL-23/Th17 pathway activity. Our findings revealed that the critical factors associated with psoriasis, such as clinical appearance, skin erythema and scaling score, skin thickness, the number of infiltrated IL-17-producing T cells, and IL-23-producing dendritic cells, are significantly improved upon injecting IDO-expressing fibroblasts.

**Materials and Methods**

**Preparation of IDO-expressing Fibroblasts**

As previously reported\textsuperscript{14}, primary dermal fibroblasts from allogeneic B6 mice were isolated from skin biopsies and transduced with a lentiviral vector that contained IDO and Red Cherry gene. Following verification of IDO expression and enzyme activity, these cells were used for intraleisional injection of psoriatic affected areas.

**Induction of Psoriasis-like Condition**

Eight- to 10-wk female BALB/c mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Mice received a daily topical dose of 55 mg of IMQ cream (5%; Aldara; 3M Pharmaceuticals, London, Ontario, Canada) on the shaved areas of the mouse back and 5 mg on the right ear for 6 d to generate localized and generalized psoriasis. This dose was determined to induce psoriasis-like skin inflammation on day 3. On day 3, mice were divided into 5 groups, no IMQ treatment (normal), IMQ-treated (Pso.), IMQ plus either medium (Sham), 4 × 10\textsuperscript{6} non-IDO fibroblast (Pso. + Fib), or 4 × 10\textsuperscript{6} IDO-Red Cherry-expressing fibroblast injected (Pso. + IDOFib). Mice were intraleionally injected with either 4 × 10\textsuperscript{6} cells or control fibroblasts/100 µL of medium/spot on dorsal areas (4 spots/mouse).

The lesions were photographed every other day. The presence of erythema and scaling on the back and ears were scored on a scale from 0 to 4 by an unbiased observer (0, none; 1, slight; 2, moderate; 3, marked; and 4, very marked). Skin and ear thickness were measured every other day using the digital caliper. Upon euthanizing the mice on day 9, the size and weight of the auxiliary and inguinal lymph nodes and spleen were taken and evaluated.

**Flow Cytometry**

Mice were euthanized on day 9, and dorsal skins, right ears, and lymph nodes were collected and minced and digested with collagenase D (Sigma-Aldrich, Oakville, Ontario, Canada) (1 mg/mL) for 30 min. Samples were then gently pressed against 40-µm nylon mesh to pass through and release cells into a culture medium. Cell suspensions from the skin of the lesion, right ears, and lymph nodes were used, and the number of the granulocytes and macrophages were determined by their surface markers using fluorescein isothiocyanate (FITC)-conjugated anti-Gr-1 (eBiosciences, San Diego, CA, USA) for granulocytes, APC-conjugated anti-F4-80 (eBiosciences), and phycoerythrin (PE)-conjugated anti-CD11b for macrophages in 1% fetal bovine serum + phosphate buffered saline (FBS + PBS). In order to characterize IL-17-producing T cells and IL-23-producing Dendritic Cells (DCs), cell suspensions from the skin, right ears, and lymph nodes were cultured and stimulated with stimulating Cocktail (plus protein transport inhibitors; eBiosciences) overnight. To perform surface staining, 1 × 10\textsuperscript{6} cells were stained for 30 min at room temperature in 1% FBS + PBS containing the PE-conjugated anti-CD4 (eBiosciences) for T cells and FITC-conjugated anti-γδ (eBiosciences) for T cells or FITC-conjugated anti-CD11c (eBiosciences) and PE-conjugated anti-CD86 (eBiosciences) for dendritic cells. In the next step, the cells were fixed and permeabilized using a fixation–permeabilization buffer (eBioscience) and incubated for 45 min at 4 °C. Cells were then washed once with permeabilization buffer (eBioscience) followed by intracellular staining using eFleur-conjugated anti-mouse IL-17 (0.5 µg per 100 µL) and eFleur-conjugated anti-mouse IL-23 (0.5 µg per 100 µL; eBioscience). Cells were analyzed using a BD Accuri\textsuperscript{TM} C6 Flow Cytometer, gates on physical parameters. A total of 20,000 events were recorded for each assay.

**Immunohistochemical Staining**

Lesional areas were harvested at the end point of experiments, fixed in 10% buffered formalin solution, and embedded in paraffin. Tissue sections 5 µm thick were prepared and stained with hematoxylin and eosin (H&E) to evaluate the epidermal thickness. Sections were rehydrated, and nonspecific binding was blocked. In another set of experiments, upon blocking nonspecific binding, sections were incubated overnight at 4 °C with rabbit anti-CD3 primary antibodies (1:50 dilution; Abcam, Cambridge, MA, USA). Sections were then washed and incubated with rhodamine goat anti-rat immunoglobulin G secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA) for 45 min. Finally, the slides were dehydrated and mounted in Permount (Fisherbrand, Pittsburgh, PA, USA).

**Statistical Analysis**

Data are reported as a mean ± standard deviation of 3 or more independent set of experiments. The statistical differences of mean value among treated and control groups were tested with one-way analysis of variance followed by post
hoc comparisons using Bonferroni correction. A value less than 0.05 was considered statistically significant.

**Ethics Statement**

All methods and procedures as well as the use of animals and tissue specimens derived from animals were approved by the Animal Ethics Committee of the University of British Columbia. Care and maintenance of all animals used in this study were in accordance with the principles of laboratory animal care and the guidelines of the institutional Animal Policy and Welfare Committee at The University of British Columbia.

**Results**

**Intrallesional Injection of IDO-expressing Fibroblasts Improves Clinical Appearance of Psoriatic-like Lesion**

Daily topical application of IMQ caused skin erythema as early as day 3 and remained high up to day 9 tested (Fig. 1a). However, intrallesional injection of IDO-expressing fibroblasts, and to a lesser extent, non-IDO-expressing fibroblast significantly improved psoriatic-induced erythema (Fig. 1a).

Using fluorescence confocal microscopy, the IDO- and Red Cherry-expressing fibroblasts remained in the dermis (Fig. 1b) and some of them migrated to local auxiliary lymph nodes (Fig. 1c). The size and weight of the auxiliary lymph nodes (numbers 1 to 3, Fig. 1d), taken from psoriatic mice treated with intrallesional injection of IDO (6.2 ± 0.8 vs. 15.3 ± 0.6 mg, n = 3, P value < 0.01) and, to a lesser extent, non-IDO-expressing cells (11.7 ± 1.6 vs. 15.3 ± 0.6 mg, n = 3, P value < 0.01), were markedly less than those taken from the psoriatic mice (Fig. 1d and e). No significant change has been detected in the weight of inguinal lymph nodes (data not shown). Our data revealed that significantly less erythema and silver scales scoring skin and ears of mice received intrallesional injection of IDO-expressing fibroblasts than nontreated positive controls (Fig. 1f and g).

**Skin Thickness Is Reduced in Psoriatic Animals that Received IDO-expressing Fibroblasts**

As shown in Fig. 2a, upon daily application of IMQ cream, skin thickness significantly increased on day 4 as compared to day 0 (0.69 ± 0.0 vs. 0.53 ± 0.03 mm, n = 12, P value < 0.01). This thickness remained the same for sham and Pso. groups on day 6 compared to day 4 (0.68 ± 0.02 vs. 0.70 ± 0.03 mm and 0.66 ± 0.0 mm vs. 0.68 ± 0.07, n = 3, P value > 0.05). However, this increase was abrogated upon injection of IDO-expressing fibroblasts (0.6 ± 0.05 vs. 0.69 ± 0.07 mm, n = 3, P value > 0.05). This further reduced up to day 9 (0.54 ± 0.05 vs. 0.69 ± 0.07 mm, n = 3, P value < 0.01) tested (Fig. 2a). Similarly, daily application of IMQ cream increased the ear thickness at day 4 as compared to day 0 (11.1 ± 0.63 vs. 8.8 ± 0.43 mm, n = 12, P value < 0.01; Fig. 2b). Our data showed no significant changes in ear thickness in mice with the injection of IDO-expressing fibroblasts on day 6 (10.30 ± 0.58 vs. 11.00 ± 0.58 mm, n = 3, P value > 0.05) and day 9 (10.30 ± 0.58 vs. 11.00 ± 0.58 mm, n = 3, P value > 0.05) as compared to that of day 4 (Fig. 2b). However, there was a marked increase in ear thickness in mice left untreated (Pso.; 14.33 ± 0.58 vs. 10.50 ± 0.00 mm, n = 3, P value < 0.01), treated with injecting medium (sham; 14.7 ± 0.58 vs. 12.0 ± 1.00 mm, n = 3, P value < 0.01), or non-IDO fibroblast (12.70 ± 1.1 vs. 11.00 ± 0.58 mm, n = 3, P value < 0.01) on day 9 compared to day 4 (Fig. 2b). The result of H&E staining of psoriatic lesion showed a significant increase in the thickness of epidermal layer of skin of Pso. group (86.7 ± 16.82 vs. 11.61 ± 2.84 μm, n = 3, P value < 0.01), sham (61.72 ± 6.82 vs. 11.61 ± 2.84 μm, n = 3, P value < 0.01), or non-IDO fibroblast (69.19 ± 9.65 vs. 11.61 ± 2.84 μm, n = 3, P value < 0.01) compared to that of normal mice and markedly reduced in injected IDO-expressing fibroblasts compared to that of normal mice (34.34 ± 10.42 vs. 11.61 ± 2.84 μm, n = 3, P value < 0.01; Fig. 2c and d).

**Intrallesional Injection of IDO-expressing Fibroblasts Reduces Infiltration of Granulocytes and Macrophages**

Granulocytes and macrophages in psoriatic lesions were identified as CD11b+ Gr-1+ and CD11b+ F4-80+ cells, respectively. Granulocytes were gated by their characteristic forward and side-scatter profiles that represent size and granularity of cells. The total population of cells within the CD11b gate was distributed as a scatterplot of fluorescence intensity versus side scatter. Gate for Gr-1 antigen was applied to CD11b+ granulocyte population to determine the mean fluorescence intensity (MFI) and relative expression of Gr-1 in skin and ear (Fig. 3a). The frequency of CD11b+ Gr-1+ cells in psoriatic-like lesions significantly increased in those of medium injected (sham; 4.2 ± 0.3 vs. 0.3 %, n = 3, P value < 0.01), Pso. (4.5 ± 0.3 % vs. 0.9 ± 0.5 %, n = 3, P value < 0.01), and non-IDO fibroblasts injected (3.9 ± 0.3 % vs. 0.9 ± 0.5 %, n = 3, P value < 0.01) as compared to normal group (Fig. 3b and c). This increase significantly decreased in psoriatic IDO-expressing fibroblast-treated mice compared to Pso. group (2.5 ± 0.4 % vs. 4.5 ± 0.3%, n = 3, P value < 0.01). Moreover, the MFI of Gr-1 molecule significantly increased in sham (107,857.2 ± 7,050.9435 vs. 65,780.9 ± 1,260.6, n = 3, P value < 0.01), Pso. (108,011.3 ± 6,288.48 vs. 65,780.9 ± 1,260.6, n = 3, P value < 0.01), and Pso. + Fib groups (93,587.9 ± 3,310.87 vs. 65,780.9 ± 1,260.6, n = 3, P value < 0.01) compared to normal mice. However, the levels of Gr-1 decreased in the IDO-expressing fibroblast-treated mice as compared to Pso. group (72,885.4 ± 716.06 vs. 108,011.3 ± 6,288.48, n = 3, P value < 0.01; Fig. 3e). Further, our results revealed that the number of granulocytes in IMQ-treated mouse ears significantly increased in Pso. group (6.1% ± 0.8% vs. 3.1% ± 0.2%, n = 3, P value <
Fig. 1. Psoriatic-like lesions before and after treatment. Psoriasis-like skin inflammation induced in BALB/c mice by daily topical application of 5% imiquimod (IMQ) cream. On day 3, mice were either untreated or treated with intraleesionally-injecting medium, 4 × 10⁶ fibroblasts or 4 × 10⁶ indoleamine 2,3-dioxygenase (IDO)-expressing fibroblasts. The presence of erythema and scaling of the back skin and ear were scored on a scale from 0 to 4 (0, none; 1, slight; 2, moderate; 3, marked; and 4, very marked). (a) Clinical appearance of IMQ-induced psoriatic-like lesions treated and untreated on days 3 and 9. (b) Presence of IDO-expressing fibroblasts in the dermis of injected lesions on day 9. (c) Presence of IDO-Red Cherry–expressing cells in regional lymph nodes. (d and e) The size and weight of auxiliary (numbers 1 to 3), inguinal lymph nodes (numbers 4 and 5) and spleen in treated and control mice. (f and g) Back skin and ear erythema and silver scale scoring in mice received different treatments as a function of time. The significant differences have been indicated by asterisks (*; P < 0.01; n = 3).
Intralesional Injection of IDO-expressing Fibroblasts Reduces Infiltration of Other Key Immune Cells

We also asked whether intralesional injection of IDO-expressing fibroblasts influences the number of the infiltrated CD3+ T cells. The results showed a marked reduction in the number of these cells in IDO-expressing fibroblast-treated mice compared to Pso. mice (4.3±0.1% vs. 11.3±1.0%, n=3, P value < 0.01; Fig. 4b and c). The frequency of macrophages also significantly increased in the psoriatic ear lesions of Pso. (2.8±0.1% vs. 0.7±0.1%, n=3, P value < 0.01), sham (2.5±0.2% vs. 0.7±0.1%, n=3, P value < 0.01), and non-IDO fibroblast-treated lesions (2.6±0.2% vs. 0.7±0.1%, n=3, P value < 0.01; Fig. 4b and d). IDO cell therapy reduced the number of these cells in the ear compared to Pso. mice (0.8±0.2% vs. 2.7±0.1%, n=3, P value < 0.01; Fig. 4b and d). MFI of F4-80 was significantly decreased in the skin (37,254.4±358.0 vs. 93,444.1±1,732.1, n=3, P value < 0.01) and ear (30,344.1±176.4 vs. 65,677.8±1,347.0, n=3, P value < 0.01) of IDO-expressing fibroblast-treated mice as compared to the Pso. group (Fig. 4e and f).
Fig. 3. The frequency of CD11b⁺ Gr-1⁺ cells in the skin, ear, and lymph nodes after cell therapy. Upon euthanizing mice on day 9, the dorsal skins and right ears were collected. After obtaining single-cell suspensions, cells were stimulated in Cell Stimulation Cocktail overnight. Granulocytes were stained for specific surface markers for 30 min at room temperature in 1% fetal bovine serum + phosphate buffered saline–containing fluorescein isothiocyanate-conjugated anti-Gr-1 and phycoerythrin-conjugated anti-CD11b. (a) Representative flow cytometry plots of gating. (b) Representative flow cytometry plots of Gr-1⁺ CD11b⁺ cells in skin and ear. (c and d) Quantitative analysis of granulocytes in skin and ear, respectively. (e and f) Mean fluorescence intensity (MFI) of Gr-1 in skin and ear, respectively. Pso. ear, right ear which has received 5 mg imiquimod cream. The significant differences have been indicated by asterisks (*; P < 0.01; n = 3).
Fig. 4. The frequency of CD11b⁺ F4-80⁺ cells in the skin and ear after cell therapy. Upon euthanizing mice on day 9, the dorsal skins and right ears were collected. After obtaining single-cell suspensions, cells were stimulated in Cell Stimulation Cocktail overnight. Monocytes were stained for specific surface markers for 30 min at room temperature in 1% fetal bovine serum + phosphate buffered saline–containing adenomatous polyposis coli–conjugated anti-F4-80 and phycoerythrin-conjugated anti-CD11b. (a) Representative flow cytometry plots of gating. (b) Representative flow cytometry plots of F4-80⁺ CD11b⁺ cells in skin and ear. (c and d) Quantitative analysis of monocytes in skin and ear, respectively. (e and f) Mean fluorescence intensity (MFI) of F4-80 in skin and ear, respectively. Pso. ear, right ear which has received 5 mg imiquimod cream. The significant differences have been indicated by asterisks (*; P < 0.01; n = 3).
Indoleamine 2,3-dioxygenase–expressing fibroblasts reduce infiltration of T cells in the skin. The presence of CD3 T cells in skin sections. Single immunofluorescence staining for CD3 was done for 5-μm thick sections of skin taken on day 9 using rabbit anti-CD3 primary antibodies and rhodamine goat anti-rat immunoglobulin G as the secondary antibody.

Fig. 5. Indoleamine 2,3-dioxygenase–expressing fibroblasts reduce infiltration of T cells in the skin. The presence of CD3 T cells in skin sections. Single immunofluorescence staining for CD3 was done for 5-μm thick sections of skin taken on day 9 using rabbit anti-CD3 primary antibodies and rhodamine goat anti-rat immunoglobulin G as the secondary antibody.
Indoleamine 2,3-dioxygenase–expressing fibroblasts suppress infiltration of IL-17+γδ+ T cells in skin, ear, and lymph node of psoriatic mice. Upon euthanizing mice on day 9, the dorsal skins, right ears, and lymph nodes were collected. After obtaining single-cell suspensions, cells were stimulated in Cell Stimulation Cocktail overnight. T cells were stained for their surface and intracellular markers in 1% fetal bovine serum + phosphate buffered saline–containing fluorescein isothiocyanate–conjugated anti-γδ and eFleur-conjugated anti-IL-17. (a) Representative flow cytometry plots of gating. (b) Representative flow cytometry plots of IL-17+γδ+ T cells in skin, ear, and lymph nodes. (c to e) Quantitative analysis of IL-17+γδ+ T cells in skin, ear, and lymph nodes, respectively. (f to h) Mean fluorescence intensity (MFI) of IL-17 in skin, ear, and lymph nodes, respectively. PsO. ear, right ear which has received 5 mg imiquimod cream. The significant differences have been indicated by asterisks (*; P < 0.01; n = 3).
compared to normal mice. The results further showed no significant changes in the frequency of these cells in sham groups compared to Pso. skin (6.1% ± 1.0% vs. 6.9% ± 0.6%, n = 3, P value > 0.05), ear (3.8% ± 0.4% vs. 3.7% ± 0.3%, n = 3, P value > 0.05), and lymph nodes (8.2% ± 1.7% vs. 6.8% ± 0.5%, n = 3, P value > 0.05).
number of these cells significantly decreased in IDO-expressing fibroblast-treated groups compared to Pso. mice both in skin (1.9% ± 0.3% vs. 6.9% ± 0.6%, n = 3, P value < 0.01) and ear (0.5% ± 0.2% vs. 3.7% ± 0.3%, n = 3, P value < 0.01). Similarly, non-IDO fibroblast injection significantly decreased the frequency of IL-17+ CD4+ T cells in skin (2.8% ± 0.4% vs. 6.9% ± 0.6%, n = 3, P value < 0.01) and ear (1.1% ± 0.3% vs. 3.7% ± 0.3%, n = 3, P value < 0.01; Fig. 7b to d). While IL-17+ CD4+ T cells frequency in lymph nodes were decreased to 3.3% ± 0.3% following IDO-expressing fibroblasts injection compared to Pso. mice (8.2% ± 1.7%, n = 3, P < 0.01), no significant change was found in the number of these cells in non-IDO fibroblast injected mice compared to Pso. mice (5.2% ± 0.3% vs. 8.2% ± 1.7%, n = 3, P value > 0.05; Fig. 7b and e). IDO-expressing fibroblasts significantly decreased the MFI of IL-17 of mouse skin (12,364.8 ± 268.6, n = 3, P value < 0.01), and lymph node (14,738.0 ± 84.2 vs. 21,454.0 ± 349.7, n = 3, P value < 0.01) compared to Pso. group (Fig. 7f to h).

**IDO Cell Therapy Suppressed Infiltration of IL-17+ T Cells and IL-23+ DCs**

As IL-23 plays a central role in the Th17 cell expansion, we tested the effect of IDO cell therapy on the number of IL-23-producing DCs. Monocytes were gated by their characteristic forward and side-scatter profiles that represent size and granularity of cells. Gate for IL-23 antigen was applied to As interactions between T cells and antigen-presenting cells in lymph nodes are crucial for initiating cell-mediated adaptive immune responses, many studies confirmed the capacity of fibroblasts as nonprofessional APCs when migrated to lymph node. In our study, we found that
Fig. 8. Flow cytometry analysis of the percentage of IL-23+ dendritic cells in skin, ear, and lymph nodes. Upon euthanizing mice on day 9, the dorsal skins, right ears, and lymph nodes were collected. After obtaining single-cell suspensions, cells were stimulated in Cell Stimulation Cocktail overnight. Dendritic cells were stained for their surface and intracellular markers in 1% fetal bovine serum + phosphate buffered saline–containing fluorescein isothiocyanate-conjugated anti-CD11c, phycoerythrin-conjugated anti-CD86, and eFleur-conjugated anti-IL-23. (a) Representative flow cytometry plots of gating. (b) Representative flow cytometry plots of IL-23+ CD11c+ DCs in skin, ear, and lymph nodes, respectively. (c to e) Quantitative analysis of IL-23+ CD11c+ DCs in skin, ear, and lymph nodes, respectively. (f to h) Mean fluorescence intensity (MFI) of IL-23 in skin, ear, and lymph nodes, respectively. Pso. ear, right ear which has received 5 mg imiquimod cream. The significant differences have been indicated by asterisks (*; \( P < 0.01 \); \( n = 3 \)).
IDO-Red Cherry-expressing cells are present in regional lymph nodes, though their interaction with naive T cells needs further study. Having said that we confirmed that the number of infiltrated CD3+ cells into psoriatic lesions that received the intralesional injection of IDO-expressing fibroblasts was significantly less than those that received either none or non-IDO fibroblasts. This might, at least in part, be due to the suppression of IL-23/IL-17. This is because the previous study showed a significant decrease in CD3+ T cells mainly in the epidermis of mice treated with anti-human IL-23 Monoclonal Antibody (mAB) in comparison to control mice.

In psoriatic patients, γδ T cells were greatly increased in affected skin and produced large amounts of IL-17. Here, we found that the number of γδ+ T cells—expressing IL-17 in psoriatic affected skin, ear lesions, and lymph nodes significantly reduced upon intralesional injection of IDO-expressing cells. Under the same experimental condition, the number of CD4+ IL-17+ cells slightly increased in skin, ear, and regional lymph nodes in psoriatic lesions compared to untreated control and that moderately reduced upon IDO-expressing cell injection. Consistent with these findings, the number of CD11c+ DCs-expressing IL-23+ and APCs (F4-80+ CD11b+) within psoriatic skin samples significantly increased in IMQ-treated mice and that markedly suppressed in mice treated with IDO-expressing cells. Interestingly, the number of granulocytes that are normally high in psoriatic lesions significantly reduced in response to intralesional injection of IDO-expressing cells. We further showed that non-IDO fibroblasts also reduce the infiltration of macrophages, CD4+ IL-17+ cells, and IL-23+ DCs but to a lesser extent than IDO-expressing fibroblasts.

This can be due the fact that fibroblasts have weak antigen presenting properties in immunomodulation. Our research group found that priming with fibroblasts has a tolerogenic impact on DCs. Fibroblast-primed DCs express coinhibitory molecules programmed cell death ligand 1 and 2 (PD-L1, PD-L1) that play a major role in suppressing the immune responses in cancer, allograft transplantation, and autoimmune disease. Our previous study has shown that upon coinhibitory activation, not only DCs lose their capacity to stimulate the proliferation of CD4 and CD8 T cells, the expression of IL-10 and IDO were increased that can suppress T cell responses. Further, it has been shown that Trp breakdown is necessary for inducing immune tolerance. Two theories have been proposed to explain how Trp catabolism facilitates tolerance. One posits that Trp breakdown suppresses immune cell proliferation by dramatically reducing the supply of this critical essential amino acid. The other postulates that downstream metabolites of Trp catabolism (such as KynA) act to suppress certain immune cells, probably by proapoptotic mechanisms.

As such, one mechanism by which the IDO-expressing fibroblasts significantly improve the clinical appearance and immunological profile of IMQ-induced psoriasis is likely to be due to the release of Kynurenin (Kyn)/Kynurenic acid (KynA). In fact, we have previously demonstrated that KynA suppresses the production and gene expression of IL-17 and IL-23 through GPCR35 activation (data not shown here).

**Conclusion**

Here, we report for the first time that IDO primary fibroblast therapy improves IMQ-induced psoriasis-like dermatitis in mice. Our data and those previously reported suggest that the immunosuppressive effects of fibroblasts plus Trp metabolites released from IDO-expressing cells are likely to be the mechanism by which IDO-expressing cells improve the clinical appearance of IMQ-induced psoriatic-like lesions through modulating the key immune cells seen in psoriatic lesions.

**Ethical Approval**

All methods and procedures as well as the use of animals and tissue specimens derived from animals were approved by the Animal Ethics Committee of the University of British Columbia.

**Statement of Human and Animal Rights**

This article does not contain any studies with humans. The care and maintenance of all animals was approved by the principles of laboratory animal care and the guidelines of the institutional Animal Policy and Welfare Committee at the University of British Columbia.

**Statement of Informed Consent**

There are no human subjects in this article and informed consent is not applicable.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study has been supported by Canadian Institutes of Health Research (CIHR)/Operating Grant MOP-136945 grant as well as partially supported by the International Brotherhood of Electrical Workers. Sanam Salimi Elizei is supported by a WorkSafe BC Research Training Award.

**References**

1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–873.
2. Nakajima K, Kanda T, Takahashi M, Shiga T, Miyoshi K, Nakajima H, Kamijima R, Tarutani M, Benson JM, Elloso MM, Gutshall LL, Naso MF, Iwakura Y, DiGiovanni J, Sano S. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol. 2011;186(7):4481–4489.
13. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, 
12. Li Y, Tredget EE, Ghaffari A, Lin X, Kilani RT, Ghahary A. 
11. Mellor AL, Munn DH. IDO expression by dendritic cells: tol-
10. Hayaishi O. Utilization of superoxide anion by indoleamine 
570 
Cell Transplantation 27(3) 
9. Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk 
8. Maclennan C, Fieschi C, Lammas DA, Picard C, Susan E, 
7. Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 
6. Genovese MC, Van Den Bosch F, Roberson SA, Bojin S, Bi-
gini IM, Ryan P, Sloan-Lancaster J. LY2439821, a humanized 
anti-interleukin-17 monoclonal antibody, in the treatment of 
patients with rheumatoid arthritis: a phase I randomized, 
double-blind, placebo-controlled, proof-of-concept study. 
Arthritis Rheum. 2010;62(4):929–939. 
7. Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 
pathway inhibitors in dermatology: usteukinumab, briakin-
umab, and secukinumab. Am J Clin Dermatol. 2011;12(2): 
113–125. 
8. Maclennan C, Fieschi C, Lammas DA, Picard C, Susan E, 
Sanal O, Maclennan JM, Holland SM, Ottenhoff THM, 
Casanova J, Kumararatne DS. Interleukin-12 and IL-23 are key cytokines for immunity against salmonellae in humans. 
J Infect Dis. 2004;190(10):1755–1757. 
9. Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk 
for major adverse cardiovascular events in patients treated with 
anti-IL-12/23 biological agents for chronic plaque psoriasis: a 
meta-analysis of randomized controlled trials. J Eur Acad 
Dermatol Venereol. 2013;27(5):622–627. 
10. Hayaishi O. Utilization of superoxide anion by indoleamine 
oxidase-catalyzed tryptophan and indoleamine oxidation. 
Adv Exp Med Biol. 1996;398:285–289. 
11. Mellor AL, Munn DH. IDO expression by dendritic cells: toler-
ance and tryptophan catabolism. Nat Rev Immunol. 2004; 
1217(1):45–59. 
12. Li Y, Tredget EE, Ghaffari A, Lin X, Kilani RT, Ghahary A. 
Local expression of indoleamine 2,3-dioxygenase protects 
grafted collagen from the imiquimod mouse model of psoriasis. 
J Immunol. 2010;185(10):5688–5691. 
13. Cay I, Shen X, Ding C, Qi C, Li K, Li X, Jala VR, Zhang H, Wang 
T, Zheng J, Jun Yan. Pivotal role of dermal IL-17-producing γδ 
T cells in skin inflammation. Immunity. 2011;35(4):596–610. 
14. Haniffa MA, Wang X, Holtick U, Rae M, Isaacs JD, Dickinson 
AM, Hilkens CMU, Collin MP. Adult human fibroblasts are 
potent immunoregulatory cells and functionally equivalent to 
mesenchymal stem cells. J Immunol. 2007;179:1595–1604. 
15. Pinchuk IV, Beswick EJ, Saada JI, Boya G, Schmitt D, Raju 
GS, Brenmoehl J, Rogler G, Reyes VE, Powell DW. Human 
colonic myofibroblasts promote expansion of CD4+ 
CD25high Foxp3+ regulatory T cells. Gastroenterology. 
2011;140(7):2019–2030. 
16. Topleian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-
H1(PD-L1) pathway to activate anti-tumor immunity. Curr 
Opin Immunol. 2012;24(2):207–212. 
17. Sandner SE, Clarkson MR, Salama AD, Sanchez-Fueyo A, 
Domenig C, Habicht A, Najafian N, Yagita H, Azuma M, 
Turka LA, Sayegh MH. Role of the programmed death-1 path-
way in regulation of alloimmune responses in vivo. J Immunol. 
2005;174(6):3408–3415. 
18. Fife BT, Pauken KE. The role of the PD-1 pathway in auto-
immunity and peripheral tolerance. Ann N Y Acad Sci. 2011; 
1217(1):45–59. 
19. Khosravi-Maharlooei M, Pakyari M, Jalili RB, Salimi-Elizei S, 
Lai JCY, Poormasjedi-Meibod M, Kilani RT, Dutz J, Ghahary 
A. Tolerogenic effect of mouse fibroblasts on dendritic cells. 
Immunology. 2016;148(1):22–33. 
20. Moffett JR, Namboodiri MA. Tryptophan and the immune 
response. Immunol Cell Biol. 2003;81(4):247–265.